Completed Enrollment

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

I8J-MC-JYCA -

The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Advanced Solid Tumor
What the trial is testing?
Ramucirumab, Abemaciclib, Merestinib, LY3300054
Could I receive a Placebo?
No
Enrollment Goal
215
Trial Dates
Jun 29, 2016 - Jul 2024
How long will I be in the trial?
The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have diagnosis of advanced solid tumor confirmed by histology or cytology

  • Participants entering the phase 1a dose escalation must submit, if available, an archival tumor tissue sample

  • Participants participating ONLY in the phase 1b expansion must submit tissue sample from either a newly obtained core or excisional biopsy of a tumor lesion or a recent (3 years since last documented progression of disease.) biopsy

Participants Must Not:

  • Participant must not have a serious concomitant systemic disorder including HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids

  • Participant must not have a bowel obstruction or chronic diarrhea

  • Participant must not have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment

  • Participant must not have received a live vaccine within 30 days before the first dose of study treatment

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources

Cancer Research

Lilly has been involved in cancer research for more than fifty years, working to improve the lives of people living with cancer. Learn more about cancer research at Lilly and how you can make an impact.

Learn More

Learn About Our Early and Metastatic Breast Cancer Research

With the help of research study participants, we are learning potential new ways to improve Breast Cancer health outcomes.

Learn More

Prostate Cancer Research

By volunteering to take part in Prostate cancer clinical trials, you may be able to play an important role in the research and development of potential new treatments and medicines. We understand that when you or a loved one take part in a clinical trial, it is a big decision. It is important for you to understand why the research is being carried out and what taking part will mean for you. Learn more about Lilly

Prostate Cancer Research

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.